A novel marker and therapeutic target of breast cancer HER2 and trastuzumab
- VernacularTitle:乳腺癌新的生物标志物及其治疗靶点——HER2及trastuzumab的研究进展
- Author:
Xiaojiang WU
;
Keneng CHEN
;
Guangwei XUE
;
- Publication Type:Journal Article
- Keywords:
HER2;
breast cancer;
monoclonal antibody
- From:China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the most common tumors in the world. HER2 and anti HER2 monoclonal antibody (Herceptin) has been a focus of breast cancer study in recent years. It is believed that HER2 and anti HER2 monoclonal antibody (Herceptin) may be a novel independent prognostic marker and therapeutic target for breast cancer. Herceptin, anti HER2 monoclonal antibody, has been proved to be an effective agent for breast cancer in late stage diseases, recurrent and metastatic lesion.
